Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: JACC: CardioOncology State-of-the-Art Review.
Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: JACC: CardioOncology State-of-the-Art Review.
复制标题
DOI：
10.1016/j.jaccao.2022.11.011
复制
发表时间：
2022-12
影响因子：
11.1
通讯作者：
Neilan, Tomas G.
中科院分区：
文献类型：
--
作者：
Suero-Abreu, Giselle Alexandra;Zanni, Markella, V;Neilan, Tomas G.
随着免疫检查点抑制剂（ICIs）临床应用的扩大，我们对这些药物潜在不良反应的了解也在不断扩大。新出现的证据支持ICI治疗与加速动脉粥样硬化和动脉粥样硬化性心血管（CV）事件之间的关联。我们讨论了支持抑制这些免疫检查点对动脉粥样硬化性心血管疾病的影响的生物学合理性和临床证据。此外，我们提供了潜在的诊断和药理学策略的观点，以降低动脉粥样硬化的风险在ici治疗的患者。我们对ici相关动脉粥样硬化病理生理学的了解尚处于早期阶段。需要进一步的研究来确定将ICI治疗与动脉粥样硬化联系起来的机制，利用ICI治疗为心血管生物学提供的见解，并开发可靠的方法来管理可能存在动脉粥样硬化性心血管疾病风险的不断扩大的患者队列。免疫检查点抑制剂（ICI）治疗与动脉粥样硬化加速介导的动脉粥样硬化性心血管事件风险增加相关。ici相关动脉粥样硬化的病理生理机制尚不完全清楚，但可能与炎症和免疫失调有关。在ICI治疗期间和之后，有必要提高对潜在动脉粥样硬化性心血管事件的认识。优化心血管危险因素和药物干预可能有助于降低动脉粥样硬化性心血管风险，改善ci治疗患者的预后。
As the clinical applications of immune checkpoint inhibitors (ICIs) expand, our knowledge of the potential adverse effects of these drugs continues to broaden. Emerging evidence supports the association between ICI therapy with accelerated atherosclerosis and atherosclerotic cardiovascular (CV) events. We discuss the biological plausibility and the clinical evidence supporting an effect of inhibition of these immune checkpoints on atherosclerotic CV disease. Further, we provide a perspective on potential diagnostic and pharmacological strategies to reduce atherosclerotic risk in ICI-treated patients. Our understanding of the pathophysiology of ICI-related atherosclerosis is in its early stages. Further research is needed to identify the mechanisms linking ICI therapy to atherosclerosis, leverage the insight that ICI therapy provides into CV biology, and develop robust approaches to manage the expanding cohort of patients who may be at risk for atherosclerotic CV disease. Immune checkpoint inhibitor (ICI) therapy is associated with an increased risk of atherosclerotic CV events likely mediated by accelerated atherosclerosis. The pathophysiological mechanism of ICI-related atherosclerosis is incompletely understood but may be linked to inflammation and immune dysregulation. There is a need for heightened awareness of potential atherosclerotic CV events during and after ICI treatment. Optimization of CV risk factors and pharmacological interventions may help mitigate atherosclerotic CV risk and improve the prognosis of ICI-treated patients.
登录
查看更多内容
影响因子：
15.9
作者：
Baitsch, Lukas;Baumgaertner, Petra;Speiser, Daniel E.
通讯作者：
Speiser, Daniel E.
影响因子：
7.5
作者：
Ansell, Stephen M.;Flinn, Ian;Yellin, Michael J.
通讯作者：
Yellin, Michael J.
影响因子：
6.2
作者：
Cautela, Jennifer;Rouby, Franck;Thuny, Franck
通讯作者：
Thuny, Franck
影响因子：
5.3
作者：
Afek, A;Harats, D;George, J
通讯作者：
George, J
影响因子：
3.7
作者：
Cochain C;Chaudhari SM;Koch M;Wiendl H;Eckstein HH;Zernecke A
通讯作者：
Zernecke A